BTYNB, the first identified IGF2BP1 inhibitor, suppresses melanoma and ovarian cancer cell proliferation by blocking IGF2BP1’s interaction with c-Myc mRNA.716 BTYNB’s therapeutic effects are being studied across various tumor models, including esophageal squamous carcinoma,717 neuroblastoma,718 and cholangiocarcinoma.719 CWI1-2 and JX5 are novel IGF2BP2 inhibitors with antileukemic activities that inactivate the Notch1 signaling pathway. The gene discussed is IGF2BP1; the disease is neoplasm.